Results 141 to 150 of about 160,899 (200)
Genetic, neuropeptidergic, and cardiometabolic interplay in female central precocious puberty. [PDF]
Cardiovasc Endocrinol MetabMusayeva AK, Amirova MF.
europepmc +1 more source
A perspective on precision therapeutics in polycystic ovary syndrome: integrating multi-omics, AI-driven stratification, and emerging biologics. [PDF]
Front Endocrinol (Lausanne)Pinton P.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Neurokinin-1 Receptor Antagonists as Anticancer Drugs
Letters in Drug Design and Discovery, 2019Human tumor cells lines and tumor samples overexpress the neurokinin-1 receptor (NK-1R). Substance P (SP), after binding to NK-1Rs, induces tumor cell proliferation, an antiapoptotic effect and promotes angiogenesis and the migration of cancer cells for ...
Rafael Coveñas, MIGUEL Munoz
exaly +4 more sources
Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach
Anti-Cancer Agents in Medicinal Chemistry, 2019BACKGROUND In adults, the most lethal and frequent primary brain tumor is glioblastoma. Despite multimodal aggressive therapies, the median survival time after diagnosis is around 15 months.
Rafael Coveñas, MIGUEL Munoz
exaly +4 more sources
Safety of neurokinin-1 receptor antagonists
Expert Opinion on Drug Safety, 2013The substance P (SP)/neurokinin (NK)-1 receptor system is involved in many pathological processes. NK-1 receptor antagonists have many promising therapeutic indications. However, the only NK-1 receptor antagonist used in clinical practice is the drug aprepitant and its intravenously administered prodrug, fosaprepitant.
Rafael Coveñas, MIGUEL Munoz
exaly +4 more sources
Potential therapeutic targets for neurokinin-1 receptor antagonists
Expert Opinion on Emerging Drugs, 2004The peptide substance P and its tachykinin receptor, neurokinin-1 (NK1), have been the focus of considerable research for their role in a variety of both central and peripheral diseases. Recent preclinical data, as well as relevant clinical findings, support the potential therapeutic value of NK1 receptor antagonists in centrally mediated disease ...
R. Duffy
semanticscholar +3 more sources
Neurokinin-1 receptor antagonists: a comprehensive patent survey
Expert Opinion on Therapeutic Patents, 2010Substance P is involved in mediating a number of biological effects such as emesis, pain, inflammation, bronchoconstriction, antitumor activity, and regulation of gastrointestinal and CNS function by binding to the neurokinin-1 (NK1) receptor. Antagonists of this receptor have the potential to be useful in the treatment of various disease conditions ...
Shih-Chung Huang, V. Korlipara
semanticscholar +3 more sources
Investigational New Drugs, 2019
The substance P/neurokinin-1 receptor system has been implicated in tumor cell proliferation. Neurokinin-1 receptor has been identified in different solid tumors but not frequently in hematopoietic malignant cells. We investigated the presence of the Neurokinin-1 receptor in acute myeloid leukemia cell lines (KG-1 and HL-60), demonstrating that acute ...
Á. Molinos-Quintana +6 more
semanticscholar +4 more sources
The substance P/neurokinin-1 receptor system has been implicated in tumor cell proliferation. Neurokinin-1 receptor has been identified in different solid tumors but not frequently in hematopoietic malignant cells. We investigated the presence of the Neurokinin-1 receptor in acute myeloid leukemia cell lines (KG-1 and HL-60), demonstrating that acute ...
Á. Molinos-Quintana +6 more
semanticscholar +4 more sources
Peptides, 2012
The last decades have seen no significant progress in extending the survival of lung cancer patients and there is an urgent need to improve current therapies. The substance P (SP)/neurokinin-1 receptor (NK-1R) system plays an important role in the development of cancer: SP and NK-1R antagonists respectively induce cell proliferation and inhibition in ...
M. Muñoz +6 more
semanticscholar +3 more sources
The last decades have seen no significant progress in extending the survival of lung cancer patients and there is an urgent need to improve current therapies. The substance P (SP)/neurokinin-1 receptor (NK-1R) system plays an important role in the development of cancer: SP and NK-1R antagonists respectively induce cell proliferation and inhibition in ...
M. Muñoz +6 more
semanticscholar +3 more sources